Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that oh-so familiar routine of meetings, online calls, and deadlines has predictably returned. But what can you do? The world, such as it is, keeps spinning. So time to give it a nudge with a cup or three of stimulation. Our choice today is the ever-flavorful butter pecan. Please feel free to join us. There is no fee involved. Meanwhile, here is the latest menu of tidbits to help you on your journey today, which we hope will be productive and meaningful. So have a smashing day and, of course, do keep in touch. …
Novartis is simplifying its structure as part of plans to save $1 billion in costs by 2024 and strengthen its business in the U.S., the world’s largest pharmaceutical market, The Financial Times reports. Three executives will leave the company as part of the restructuring, which will combine the oncology and pharmaceutical units into one innovative medicines division, with separate commercial organizations for the U.S. and international markets. Novartis is also looking for a leader for a new strategy and growth division. The company expects these changes to ensure at least 4% compound annual growth through 2026, and deliver margins at the high end of guidance of 30% in the medium term.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
